1. Home
  2. NXTC vs ABVC Comparison

NXTC vs ABVC Comparison

Compare NXTC & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextCure Inc.

NXTC

NextCure Inc.

SELL

Current Price

$6.83

Market Cap

24.8M

Sector

Health Care

ML Signal

SELL

Logo ABVC BioPharma Inc.

ABVC

ABVC BioPharma Inc.

SELL

Current Price

$0.91

Market Cap

26.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NXTC
ABVC
Founded
2015
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.8M
26.7M
IPO Year
2019
2009

Fundamental Metrics

Financial Performance
Metric
NXTC
ABVC
Price
$6.83
$0.91
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $20.00
N/A
AVG Volume (30 Days)
★ 51.7K
27.1K
Earning Date
11-10-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 7.14
EPS
N/A
★ N/A
Revenue
★ $22,378,000.00
$509,589.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$171.50
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.55
$0.71
52 Week High
$15.74
$2.94

Technical Indicators

Market Signals
Indicator
NXTC
ABVC
Relative Strength Index (RSI) 54.35 50.16
Support Level $4.28 $0.92
Resistance Level $6.66 $1.12
Average True Range (ATR) 0.80 0.07
MACD 0.09 -0.00
Stochastic Oscillator 69.35 51.81

Price Performance

Historical Comparison
NXTC
ABVC

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

About ABVC ABVC BioPharma Inc.

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.

Share on Social Networks: